Send us Fan Mail

AI can now search through a vastly wider grid of possible compounds and molecules than any human team could evaluate in a lifetime. The bottleneck is no longer discovery speed. It is verification. David Finkelshteyn, CEO of Pivotal AI, builds AI systems for pharmaceutical and life sciences use cases that can be verified, defended, and trusted. His work sits at the intersection where machine learning outputs must survive regulators, audits, and real-world consequences involving human health.

In this episode of The Signal Room, host Christopher Hutchins, Founder and CEO of Hutchins Data Strategy Consultants, sits down with David to examine why generating AI-designed drug candidates without rigorous verification is fundamentally meaningless. David explains that discovery and verification are inseparable. A model can propose thousands of novel molecules, but each must pass through pharmacokinetics screening, in vitro testing, in vivo validation, clinical target selection, and human trials. Every stage is a potential breakpoint, and AI introduces a new category of risk: when models design molecules that look unlike anything seen in nature, there is almost no historical data to predict how the human body will respond.

The conversation covers the complexity-transparency tradeoff in machine learning, where more complex tasks demand more complex models that become less explainable. David walks through what real verification looks like in drug development, including the critical importance of separating training data from validation data to avoid overfitting and data leakage. He also addresses the emerging consumer health AI landscape and offers a practical rule: give the model more context to reduce hallucination, treat it as an analytics tool rather than an inventor, request real source references, and then go see your doctor.

The episode closes with David's outlook on how verification will shift from constraint to competitive advantage as automated robotic labs begin closing the design-verification loop, reducing the time between AI-proposed candidates and physical synthesis and testing.

(00:02) Teaser: Human readiness vs. technical readiness in healthcare AI
(00:38) AI in drug discovery: expanding compound search space
(01:00) David Finkelshteyn (Pivotal AI): building defensible AI systems
(02:00) Discovery vs. verification: why validation is critical
(03:51) AI due diligence in an emerging field
(04:26) Drug development stages: synthesis to human trials
(07:08) Novel AI molecules and the verification gap
(07:48) Validation standards remain unchanged for AI
(08:20) Faster R&D: compressing timelines with AI
(09:22) COVID vaccines: early signal of AI acceleration
(09:56) Black box problem: limits of model explainability
(11:58) Complexity vs. transparency tradeoff
(12:08) Explainability gaps in clinical and regulatory settings
(13:31) Verifying AI outputs: use case, data quality, leakage risks
(16:22) Missing context in consumer health AI
(17:33) Responsible use: verify sources, consult clinicians
(19:55) Incomplete context as a primary sou

Support the show

About The Signal Room: The Signal Room is a podcast and communications platform exploring leadership, ethics, and innovation in healthcare and artificial intelligence. Hosted by Christopher Hutchins, Founder and CEO of Hutchins Data Strategy Consultants. Leadership, ethics, and innovation, amplified.

Website: https://www.hutchinsdatastrategy.com

LinkedIn: https://www.linkedin.com/in/chutchins-healthcare/

YouTube: https://www.youtube.com/@ChrisHutchinsAi

Book Chris to speak: https://www.chrisjhutchins.com